News

Article

EBX-102 Shows Promise As First Microbiome Therapeutic for Cirrhosis

Key Takeaways

  • EBX-102 demonstrated safety, tolerability, and potential efficacy in liver cirrhosis patients, with significant microbiome shifts and improved gut-brain-axis effects.
  • The study showed enhanced ammonia excretion and reduced inflammatory markers, indicating successful gut microbiota modulation.
SHOW MORE

Phase 1b data support proof-of-principle for EBX-102 across microbiome and clinical assessments as well as inflammatory biomarkers for cirrhosis.

James McIlroy, MBChB | Credit: EnteroBiotix

James McIlroy, MBChB

Credit: EnteroBiotix

EnteroBiotix Limited has announced positive results from its phase 1b Intestinal Microbiota Product in Liver Cirrhosis and Encephalopathy (IMPuLCE) study evaluating EBX-102 in patients with liver cirrhosis.1.2

Findings from the first-in-human study of EBX-102 provide evidence for proof-of-principle across multiple microbiome assessments, inflammatory biomarkers, and clinical assessments, supporting its continued development as the first microbial therapy for patients with liver disease.1

“In addition to safety and tolerability data supporting further studies, we observed multiple microbiome and systemic measurements supporting mechanistic proof-of-principle,” James McIlroy, MBChB, CEO of EnteroBiotix, said in a press release.1 “There are very large unmet medical needs in the field of advanced liver disease, and it is greatly encouraging that EBX-102 has potential efficacy in this population.”

An encapsulated full-spectrum microbiome therapeutic, EBX-102 has differentiated characteristics, such as consistency, high-bacterial diversity, and stability. It is an orally administered capsule that contains diverse full-spectrum microbial ecosystems intended to restore microbial ecology and act in concert to target multiple key disease pathways.1,2

The scalable manufacture of EBX-102 is made possible by platform manufacturing technologies and a well-developed analytical toolkit from EnteroBiotix, which controls the supply chain for its products through sophisticated MHRA-licensed manufacturing infrastructure together with its Number 2® brand, which ensures the safety, security, quality, and sufficiency of the supply of microbiota obtained from healthy human donors.1

IMPuLCE was a randomized, double-blind, placebo-controlled phase 1b study of adult participants with stable liver cirrhosis. It was conducted across 10 sites in the United Kingdom and designed to evaluate the safety, tolerability, and translational biomarker effects of 2 different doses of EBX-102.1

According to a press release from EnteroBiotix, EBX-102 was well tolerated with an acceptable safety profile. The most common adverse events were gastrointestinal, and mainly mild and self-limiting. Of note, no serious treatment-emergent adverse events were reported.1

Results showed participants receiving the higher dose of EBX-102 in cohort 2 showed significant shifts in stool bacterial microbiome composition compared to placebo, assessed by 16SrRNA sequencing. Additionally, participants receiving EBX-102 showed statistically significant changes in stool bacterial metabolites, with ongoing shotgun sequencing is ongoing and will provide additional insights into engraftment.1

Although venous ammonia concentrations remained stable in all study participants, investigators called attention to a statistically significant increase in stool ammonia concentrations in the EBX-102 treatment groups but not the placebo group, suggesting a shift towards enhanced ammonia excretion through the stool rather than absorption into the bloodstream.1

Investigators also observed a reduction in plasma lipopolysaccharide-binding protein in the EBX-102 cohorts but not in the placebo, indicative of successful modulation of the gut microbiota towards a more beneficial ecology, improved gut barrier integrity, and reduced inflammatory response.1

Of note, improvements in hospital anxiety and depression scores were observed in the treatment groups but not in the placebo group, with a stronger trend at the higher dose, indicating potential gut-brain-axis effects.1

“These exciting data demonstrate that EBX-102 is well tolerated in patients with chronic liver disease, showing promising biological effects that strongly support further clinical development,” Ewan Forrest, chief investigator of the IMPuLCE study and an honorary professor in the School of Cardiovascular and Metabolic Health at the University of Glasgow, said in a press release.1 “The observed improvement in mental health scores is particularly intriguing, and we look forward to continuing to explore the potential of EBX-102 in future liver disease trials.”

References

  1. EnteroBiotix. EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis. November 11, 2024. Accessed November 11, 2024. https://www.enterobiotix.com/news/enterobiotix-positive-clinical-results-ebx-102-liver-cirrhosis
  2. EnteroBiotix. EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy. March 28, 2024. Accessed November 11, 2024. https://www.enterobiotix.com/news/phase-2-study-of-microbiome-drug-ebx-102
Related Videos
Erin Michos, MD: HFpEF in Women and Sex-Specific Therapeutic Approaches | Image Credit: Johns Hopkins
Davide Matino, MD, MSc: Bringing Marstacimab Treatment to Hemophilia A and B
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Marlyn Mayo, MD: Improving Pruritus Management in PBC Care
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
© 2024 MJH Life Sciences

All rights reserved.